Table 1.
Description of sociodemographic and clinical samples: median split by positive psychotic symptoms.
| Psychotic patients with | Less positive symptoms (10 FEP and 11 forensic) | More positive symptoms (18 FEP and 3 forensic) | p |
|---|---|---|---|
| Positive psychotic symptomsa | 6 ± 1 | 14 ± 1 | <0.0001 |
| Age | 31.57 ± 7.69 | 29.33 ± 7.80 | 0.355 |
| MWT | 107.65 ± 13.76 | 106.11 ± 14.29 | 0.748 |
| CPZ | 162,973.29 ± 163,944.46 | 60,926 ± 131,687.29 | 0.032 |
| GAF | 54.76 ± 16.55 | 49.10 ± 13.57 | 0.239 |
| SAT: behavioral data | |||
| Mean reaction time (ms) | 262.10 ± 46.44 | 260.73 ± 52.42 | 0.929 |
| Total omissions | 0.57 ± 1.36 | 2.48 ± 6.57 | 0.201 |
| Premature responses | 5.86 ± 8.77 | 4.33 ± 4.29 | 0.479 |
| Implicit aberrant salience (ms) | 15.79 ± 10.76 | 15.10 ± 8.52 | 0.819 |
| Explicit aberrant salience (VAS%) | 12.08 ± 11.46 | 10.89 ± 8.31 | 0.702 |
Data are presented as mean ± SD.
aSum of BPRS items (suspiciousness, hallucinations, unusual thought content, and conceptual disorganization).
CPZ, cumulative chlorpromazine equivalents during the previous year; GAF, global assessment of functioning; MWT, intelligence quotient test (Mehrfachwahl-Wortschatz-Intelligenz-Test); SAT, Salience Attribution Test.